53BP1	p53-binding Protein 1
AE	Adverse Event
ALL	Acute Lymphoblastic Leukemia
AML	Acute Myeloid Leukemia
BH3	Bcl-2 Homology 3
CDK	Cyclin-dependent Kinase
CDKI	Cyclin-dependent Kinase Inhibitor
CI	Confidence Interval
CLL	Chronic Lymphocytic Leukemia
DDR	DNA Damage Repair Response
DLBCL	Diffuse Large B-cell Lymphoma
FAERS	FDA Adverse Event Reporting System
FDA	Food and Drug Administration
FL	Follicular Lymphoma
FNPVD	French National Pharmacovigilance Database
HAECs	Primary Human Aortic Endothelial Cells
HDAC	Histone Deacetylase
hTERT	Human Telomerase Reverse Transcriptase
IRB	Institutional Review Board
LDAC	Low-Dose Cytarabine
MedDRA	Medical Dictionary for Regulatory Activities
mTOR	mammalian Target of Rapamycin
PARP	Poly (ADP-ribose) Polymerase
PRR	Proportional Reporting Ratio
PT	Preferred Term
Q	Quartile
Rb	Retinoblastoma Protein
RCTs	Randomized Controlled Trials
ROR	Reporting Odds Ratio
SAGA	Senescence-associated Growth Arrest
SAHF	Senescence-associated Heterochromatin Foci
SASP	Senescence-associated Secretory Phenotype
SA-β-gal	Senescence-associated β-galactosidase
SLL	Small Lymphocytic Lymphoma
SOC	System Organ Class
TIS	Therapy-Induced Senescence
TNBC	Triple-Negative Breast Cancer
TRF2	Telomeric Repeat-binding Factor 2
WBC	White Blood Cell